See the newly-re-launched Impactiviti Collection e-newsletter! Here’s a link to the on-line sample; you can sign up to receive the Connection (~every two weeks) right here.
It’s going to be a big week for Social Media in Pharma. Here’s the scoop.
Cancer drug Nexavar shows efficacy in breast cancer – Bayer and Onyx Pharmaceuticals‘ cancer pill Nexavar has demonstrated impressive results in treating breast tumours, brokerage Baird said on Monday, citing an abstract from a medical congress…Patients given Nexavar plus Xeloda had a 74 percent improvement in the time they lived without their disease progressing….more
AstraZeneca and Nektar Therapeutics in big licensing deal – Under the agreement, AstraZeneca will develop Nektar’s late-stage drug to treat opioid-induced constipation, NKTR-118, and NKTR-119, which is in its early-stage studies to treat pain without the side effects of constipation…more
Avastin for melanoma? That could be exciting. Melanoma has been notoriously resistant to everything thrown at it.
Negotiating Skills. Presentation Skills. There’s an Impactiviti partner for those. Our best-in-class training providers can customize a program for your needs. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for information and recommendations!
Everything you always wanted to know about Instructional Design Models. It’s actually a lot more than I want to know! Hat tip: Ellen Wagner
JUST FOR FUN
100% accuracy for the weather? Announcing…The Weather Channel Classic! (spoof)
Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)
Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)
Connect with Steve Woodruff
Leave a Reply